Skip to content

Interest of the Detection of Hyper-virulent Clone ST17 of Group B Strep (GBS) for the Prevention of Neonatal GBS Meningitis

Study of the Digestive Colonization of the Newborn Children by the Streptococcus of the Group B

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01719510
Acronym
Col-Strepto B
Enrollment
949
Registered
2012-11-01
Start date
2012-11-12
Completion date
2015-06-03
Last updated
2025-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Infections Colonize With Group B Streptococci

Keywords

Group B Streptococcus,, Vaginal screening, Per partum antibiotic prophylaxis, Meningitis, Neonatal infection, PCR, Streptococcus agalactiae.

Brief summary

The main objective of this study : Demonstrate that GBS (group B streptococci) ST-17 colonize and persist to 60 days twice in the digestive tract of newborns that strains of GBS non-ST-17. Secondary objectives:Determine: * The frequency of colonization with GBS ST-17 and GBS non-ST-17 of at risk pregnant women. * The frequency of colonization of neonates by GBS ST-17 at birth. * The preferential site of colonization in the mother (rectum, vagina, breast milk). * The kinetics of colonization after birth in the newborn. * The sensitivity and specificity of different GBS detection methods (conventional phenotypic versus molecular) in the different types of samples from the mother and the newborn.

Detailed description

Women tested positive for GBS during systematic vaginal screening at 35-37 weeks, will be proposed to participate to the study and will be included after reading the information letter and signature the consent form. INCLUSION (D0 at time of delivery) In the labor ward, two women's groups 1 and 2: Group 1 = Women tested positive for GBS pre-selected and included in the protocol (see pre-inclusion) Group 2 = Women without antenatal vaginal screening and at risk of neonatal infection. For both groups, at time of delivery: At the beginning of the labour performed vaginal swabs (PV0): * one swab for GBS detection by real-time PCR using the Cepheid technique conducted in the labor ward by the midwife. * the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory. For all women included (Group 1 and Group 2 women with a positive GBS vaginal sample) will be achieved in the delivery room: 1. To the mother: A blood sample of 5 ml at the time of the implementation of the IV line. 2. A sampling of umbilical cord blood. Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home. Samples will be sent to the bacteriology laboratory and analyzed by classical bacteriological method (culture) and / or real-time PCR. For mothers, the collection of 3-5 ml of milk when breastfeeding. Monitoring schedule: Day 21 and day 60 post delivery: the following samples for search of GBS for will be performed to gather the primary endpoint: For the mother: * Vaginal sample. * Collection of 3-5 ml of breast milk when breastfeeding For the newborn: * Sample collection of feces * Swab of buccal cavity Processing bacteriological samples: All samples will be subjected to bacteriological analysis and DNA extraction for detection of GBS. GBS isolated will be identified and stored at - 80 ° C in a declared biological collection. DNA extracts will also stored at -20 ° C in a declared biological collection. All samples for microbiological analysis will be stored at - 80 ° C.

Interventions

OTHERSamples

At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection. For both groups: * one swab for GBS detection by real-time PCR * the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory. For all women included will be achieved in the delivery room: 1. To the mother: A blood sample of 5 ml at the time of the implementation of the IV line. 2. A sampling of umbilical cord blood. Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home. For mothers, the collection of 3-5 ml of milk when breastfeeding.

Sponsors

URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient having a positive vaginal swab for GBS at the end of pregnancy (PCR +). * Patient aged over 18 years * Patient who received information and agreeing to sign informed consent * Patient affiliated or beneficiary of an insurance

Exclusion criteria

\- Patient does not speak and does not understand French

Design outcomes

Primary

MeasureTime frameDescription
Detection of the hyper-virulent ST17 clone of Group B Strepat 60 days post deliveryDetection of the hyper-virulent ST17 clone of Group B Strep (GBS) in the prevention of neonatal GBS meningitis. The main objective is to demonstrate that the hypervirulent ST17 GBS clone colonizing the mother and postpartum acquired colonizes and persists at 60 days post delivery in the gut of new born significantly more than non-ST17 GBS strains.

Secondary

MeasureTime frameDescription
Digestive colonizationat day 21Digestive colonization of ST17 clone of Group B Strep in the newborns
Milk colonizationat day 21 and day 60Colonization of milk by ST17 clone of Group B Strep
Vaginal colonizationat day 21 and day 60Vaginal colonization by ST17 clone of Group B Strep
Late neonatal infectionsbetween 3 weeks and 60 daysLate neonatal infections will be observed between 3 weeks and 60 days

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026